Major depressive disorder: Psychopathology, medical management and dental implications

Journal of the American Dental Association

Volumn 132, Issue 5, 2001, Pages 629-638

  Friedlander, Arthur H ^a   Mahler, Michael E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICARIES AGENT; ANTIDEPRESSANT AGENT; FLUORIDE; SALIVA SUBSTITUTE;

AFFECT; AGED; ARTICLE; CARIOGENIC DIET; CHEMICALLY INDUCED DISORDER; DENTAL CARE; DENTAL CARIES; DEPRESSION; FATIGUE; FEMALE; HUMAN; HUMAN RELATION; MALE; MIDDLE AGED; MOUTH HYGIENE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERIODONTAL DISEASE; PREVALENCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RECURRENT DISEASE; SALIVA; SECRETION; SENSORY DYSFUNCTION; SLEEP DISORDER; SUICIDE; XEROSTOMIA;

AFFECT; AGED; ANALGESICS; ANTIDEPRESSIVE AGENTS; CARIOSTATIC AGENTS; DENTAL CARE FOR CHRONICALLY ILL; DENTAL CARIES; DEPRESSIVE DISORDER; DIET, CARIOGENIC; FATIGUE; FEMALE; FLUORIDES; HUMANS; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; ORAL HYGIENE; PATIENT EDUCATION; PERIODONTAL DISEASES; PREVALENCE; QUALITY OF LIFE; RECURRENCE; SALIVA; SALIVA, ARTIFICIAL; SENSATION DISORDERS; SLEEP DISORDERS; SUICIDE; XEROSTOMIA;

EID: 0035345388     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2001.0240     Document Type: Article

References (74)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington: American Psychiatric Association; 1994:317-89.
2. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60(suppl 20):9-15.
3. Judd LL. Pleomorphic expressions of unipolar depressive disease: summary of the 1996 CINP President's Workshop. J Affect Disord 1997;45(1-2):109-16.
4. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during long-term course of unipolar depressive disorder. Arch Gen Psychiatry 2000;57(4):375-80.
5. Druss BG, Rosenheck RA. Patterns of health care costs associated with depression and substance abuse in a national sample. Psychiatr Serv 1999;50(2):214-8.
6. Pearson SD, Katzelnick DJ, Simon GE, Manning WG, Helstad CP, Henk HJ. Depression among high utilizers of medical care. J Gen Intern Med 1999;14(8):461-8.
7. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156(7):1000-6.
8. Murray CJ, Lopez AD, eds. The global burden of disease. Cambridge, Mass.: Harvard University Press; 1996:21.
9. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence for DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51(1):8-19.
10. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276(4):293-9.
11. Andrew M, McGuffin P, Katz R. Genetic and non-genetic subtypes of major depressive disorder. Br J Psychiatry 1998;173:523-6.
12. Kendler KS, Prescott CA. A population-based twin study of lifetime major depression in men and women. Arch Gen Psychiatry 1999;56(1):39-44.
13. Patten SB. Long-term medical conditions and major depression in the Canadian population. Can J Psychiatry 1999;44(2):151-7.
14. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55(7):580-92.
15. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000;132(9):738-42.
16. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000;6(2):115-20.
17. Poewe W, Luginger E. Depression in Parkinson's disease: impediments to recognition and treatment options. Neurology 1999;52(7 suppl 3):S2-6.
18. Penninx BW, Geerlings SW, Deeg DJ, van Eijk JT, van Tilburg W, Beekman AT. Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry 1999;56(10):889-95.
19. Abraham HD, Fava M. Order of onset of substance abuse and depression in a sample of depressed outpatients. Compr Psychiatry 1999;40(1):44-50.
20. Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annan ML. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 1999;55(2-3):171-8.
21. Meagher D, Murray D. Depression. Lancet 1997;349(suppl 1): 117-20.
22. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999;156(6):837-41.
23. De Marco RR. The epidemiology of major depression: implications of occurrence, recurrence, and stress in a Canadian community sample. Can J Psychiatry 2000;45(1):67-74.
24. Musselman DL, DiBattistia C, Nathan KI, Kilts CD, Schatzberg AF, Nemeroff CB. Biology of mood disorders. In: American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington: American Psychiatric Press; 1998:550-8.
25. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 1999;877:614-37.
26. Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res 1999;91(3):127-39.
27. Scott J. Treatment of chronic depression. N Engl J Med 2000;342(20):1518-20.
28. Goldman LS, Nielsen NH, Champion HC. Awareness, diagnosis, and treatment of depression. J Gen Intern Med 1999;14(9):569-80.
29. Scott J. Where there's a will: cognitive therapy for people with chronic depressive disorders. In: Tarrier N, Wells A, Haddock G, eds. Treating complex cases: The cognitive behavioural therapy approach. Chichester, England: Wiley; 1998:81-104.
30. Clinical practice guideline number 5: depression in primary care, 2 - treatment of major depression. Rockville, Md.: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551.
31. Williams JW, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132(9): 743-56.
32. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: a meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9(1):47-53.
33. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57(4): 507-33.
34. Spigset O. Adverse reactions to selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999;20(3):277-87.
35. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998;51(3):237-54.
36. Majeroni BA, Hess A. The pharmacologic treatment of depression. J Am Board Fam Pract 1998;11(2):127-39.
37. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA 1997;278(14):1186-90.
38. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:431-59.
39. Frank E, Thase ME. Natural history and preventative treatment of recurrent mood disorders. Ann Rev Med 1999;50:453-68.
40. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342(20):1462-70.
41. Tew JD, Mulsant BH, Haskett RF, et al. Acute efficacy of ECT in the treatment of major depression in the old-old. Am J Psychiatry 1999;156(2):1865-70.
42. Blier P, de Montigny C. Serotonin and drug-induced therapeutic response in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999;21(2 suppl):91S-8S.
43. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993;328(12):839-46.
44. Dubovsky SL. Electroconvulsive therapy. In: Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry/VI. 6th ed. Baltimore: Williams & Wilkins; 1995:2129-40.
45. Bailine SH, Rifkin A, Kayne E, et al. Comparison of bifrontal and bitemporal ECT for major depression. Am J Psychiatry 2000;157(1):121-3.
46. Physicians' desk reference. 54th ed. Montvale, N.J.: Medical Economics; 2000.
47. Elter JR, Beck JD, Slade GD, Offenbacher S. Etiologic models for incident periodontal attachment loss in older adults. J Clin Periodontol 1999;26(2):113-23.
48. Monteiro da Silva AM, Oakley DA, Newman HN, Nohl FS, Lloyd HM. Psychosocial factors and adult onset rapidly progressive periodontitis. J Clin Periodontol 1996;23(8):789-94.
49. da Silva AM, Newman HN, Oakley DA. Psychosocial factors in inflammatory periodontal diseases: a review. J Clin Periodontol 1995;22:516-26.
50. Kurer JR, Watts TL, Weinman J, Gower DB. Psychological mood of regular dental attenders in relation to oral hygiene behaviour and gingival health. J Clin Periodontol 1995;22(1):52-5.
51. Moss ME, Beck JD, Kaplan BH, et al. Exploratory case-control analysis of psychosocial factors and adult periodontitis. J Periodontol 1996;67(10 suppl):1060-9.
52. Schleifer SJ, Keller SE, Bartlett JA, Eckholdt HM, Delaney BR. Immunity in young adults with major depressive disorder. Am J Psychiatry 1996;153(4):477-82.
53. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32(6):692-8.
54. Brown ES, Hong SC. Antidepressant-induced bruxism successfully treated with gabapentin. JADA 1999;130(10):1467-9.
55. Study shows link between antidepressants, bruxism. JADA 2000;131(3):297.
56. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry 1999;60(12):857-60.
57. Amsterdam JD, Settle RG, Doty RL, Abelman E, Winokur A. Taste and smell perception in depression. Biol Psychiatry 1987;22(2):1481-5.
58. Anttila SS, Knuuttila ML, Sakki TK. Depressive symptoms favor abundant growth of salivary lactobacilli. Psychosom Med 1999;61(4): 508-12.
59. Wallin MS, Rissanen AM. Food and mood: relationship between food, serotonin and affective disorders. Acta Psychiatr Scand Suppl 1994;377:36-40.
60. Christensen L, Somers S. Comparison of nutrient intake among depressed and nondepressed individuals. Int J Eat Disord 1996;20(1): 105-9.
61. Potter W, Manji H, Rudorfer M. Tricyclics and tetracyclics. In: Schatzberg A, Nemeroff C, eds. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington: American Psychiatric Press; 1998:199-218.
62. Gallagher RM, Marbach JJ, Raphael KG, Dohrenwend BP, Cloitre M. Is major depression comorbid with temporomandibular pain and dysfunction syndrome? A pilot study. Clin J Pain 1991;7(3):219-25.
63. Korszun A, Hinderstein B, Wong M. Comorbidity of depression with chronic facial pain and temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82(5):496-500.
64. Gatchel RJ, Garofalo JP, Ellis E, Holt C. Major psychological disorders in acute and chronic TMD: an initial examination. JADA 1996;127(9):1365-74.
65. Sternberg EM, Young WS, Bernardini R, et al. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989;86(12):4771-5.
66. Marbach JJ. Medically unexplained chronic orofacial pain: temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia. Med Clin North Am 1999;83(3):691-710.
67. Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med 1999;28(8):350-4.
68. Drage LA, Rogers RS. Clinical assessment and outcome in 70 patients with complaints of burning or sore mouth symptoms. Mayo Clin Proc 1999;74(3):223-8.
69. Demange C, Husson C, Poi-Vet D, Escande JP. Paresthesies buccales psychogenes et depresion: une approche psychanalytique [Burning mouth syndromes and depression: a psychoanalytic approach]. Rev Stomatol Chir Maxillofac 1996;97(4):244-52.
70. Korszun A, Ship JA. Diagnosing depression in patients with chronic pain. JADA 1997;128:1680-6.
71. Callahan AM, Marangell LB, Ketter TA. Evaluating the clinical significance of drug interactions: a systematic approach. Harv Rev Psychiatry 1996;4(3):153-8.
72. Ganzberg S. Psychoactive drugs. In: ADA guide to dental therapeutics. 2nd ed. Chicago: ADA Publishing, a division of ADA Business Enterprises Inc.; 2000:376-405.
73. Broquet KE. Status of treatment of depression. South Med J 1999;92(9):846-56.
74. Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors - part V of a series. JADA 1999;130(5):701-9.